Free shipping on all orders over $ 500

Nerandomilast (BI 1015550)

Cat. No. M25404

All AbMole products are for research use only, cannot be used for human consumption.

Nerandomilast (BI 1015550) Structure
Synonym:

BI-1015550

Size Price Availability Quantity
1mg USD 62  USD62 In stock
5mg USD 133  USD133 In stock
10mg USD 215  USD215 In stock
25mg USD 419  USD419 In stock
50mg USD 623  USD623 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Nerandomilast (BI 1015550) is a novel, orally active phosphodiesterase 4B (PDE4B) inhibitor (IC50 = 7.2 nM) with anti-fibrotic and anti-inflammatory effects.

In vitro, Nerandomilast (BI 1015550) inhibits lipopolysaccharide (LPS)-induced tumor necrosis factor-α (TNF-α) and phytohemagglutinin-induced interleukin-2 synthesis in human peripheral blood mononuclear cells, as well as LPS-induced TNF-α synthesis in human and rat whole blood.

In vivo, oral BI 1015550 shows potent anti-inflammatory activity in mice by inhibiting LPS-induced TNF-α synthesis ex vivo and in Suncus murinus by inhibiting neutrophil influx into bronchoalveolar lavage fluid stimulated by nebulized LPS.

Nerandomilast (BI 1015550) inhibited transforming growth factor-β-stimulated myofibroblast transformation and the mRNA expression of various extracellular matrix proteins, as well as basic fibroblast growth factor plus interleukin-1β-induced cell proliferation.

Chemical Information
Molecular Weight 448.97
Formula C20H25ClN6O2S
CAS Number 1423719-30-5
Solubility (25°C) DMSO 6 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Giacomo Sgalla, et al. Expert Opin Investig Drugs. BI 1015550: an investigational phosphodiesterase 4B (PDE4B) inhibitor for lung function decline in idiopathic pulmonary fibrosis (IPF)

[2] Luca Richeldi, et al. J Comp Eff Res. Plain language summary: Clinical study of BI 1015550 as a potential treatment for idiopathic pulmonary fibrosis

[3] Toby M Maher, et al. ERJ Open Res. Phase I studies of BI 1015550, a preferential phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis

[4] Luca Richeldi, et al. N Engl J Med. Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis

[5] Franziska Elena Herrmann, et al. Front Pharmacol. BI 1015550 is a PDE4B Inhibitor and a Clinical Drυg Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis

Related PDE Products
MR-L2

MR-L2 is a reversible and noncompetitive allosteric activator of long-isoform phosphodiesterase-4 (PDE4), activates representative PDE4 long-isoform variants (PDE4A4, PDE4B1, PDE4C3, PDE4D5). MR-L2 suppresses PGE2-induced MDCK cell cyst formation with an EC50 of 1.2 μM.

MMPX

MMPX is a potent PDE1 inhibitor.

T-0156 

T-0156 is a potent and selective phosphodiesterase type 5 (PDE5) inhibitor.

TPN171 

TPN171 is a potent, selective and oral bioavailable inhibitor of phosphodiesterase type 5 (PDE5) with an IC50 of 0.62 nM, being developed for the treatment of pulmonary arterial hypertension (PAH).

Mesopram

Mesopram (Daxalipram) is an orally active phosphodiesterase (PDE) 4 inhibitor.

  Catalog
Abmole Inhibitor Catalog




Keywords: Nerandomilast (BI 1015550), BI-1015550 supplier, PDE, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.